Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Natco Pharma
Mid Cap•4,016 Employees•IPO 1995
Current Price
₹947.75
-8.1 (-0.85%)Updated
Today's Range
940.7
₹947.75
990
52 Week Range
52W Low₹726.80
52W High₹1059.00
₹947.75
Downside30.40%
Upside11.74%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹15,842.27 Cr
Market Cap
Total market value of companyP/E Ratio
10.30
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
1.65
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹85.91
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
11.38%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
32.80%
ROCE
Return on Capital Employed. >15% is goodNet Margin
35.07%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
32.97%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
18.26%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-2.47%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-28.10%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.04
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹424.71
Book Value
Net asset value per shareDividend Yield
0.57%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
49.50%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Natco Pharma exhibits a robust Return on Equity (ROE) of 28.00%, signifying efficient capital utilization and strong profitability. Coupled with a high Return on Capital Employed (ROCE) of 32.80%, this indicates excellent operational efficiency and asset management.
- •The company boasts a remarkably low Price-to-Earnings (P/E) ratio of 8.73, suggesting that the stock might be undervalued relative to its earnings. This presents a potentially attractive entry point for investors seeking value.
Weaknesses
4 points- •While quarterly profits show growth, there's significant volatility in sales (-2.47%) and profit (-28.10%) figures across quarters. This inconsistency in performance presents a risk to consistent returns for investors.
- •Although the debt-to-equity ratio is low at 0.04, the absolute debt level of ₹279 crore might still pose a constraint on future growth, especially during economic downturns or unexpected financial challenges.
Opportunities
3 points- •Natco Pharma's strong financial health, indicated by its 28.00% ROE and 32.80% ROCE, positions it well to pursue strategic acquisitions or expand into new therapeutic areas, driving future growth.
- •The company's significantly lower P/E ratio of 8.73 compared to industry peers (e.g., Sun Pharma 35.90) suggests potential for a valuation re-rating as its growth stabilizes and market confidence improves.
Threats
4 points- •Intense competition from larger, well-established pharmaceutical players like Sun Pharma (Market Cap ₹411665 Cr) and Divi's Lab (Market Cap ₹173033 Cr) could limit Natco Pharma's market share and pricing power.
- •The pharmaceutical industry is subject to stringent regulatory changes and approvals, which could impact product launches, increase compliance costs, or lead to delays, affecting profitability.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
SADA SIVA RAO. NANNAPANENI | 19 Dec 2024 | 21 Dec 2024 | 71,051 | 5,000 | ₹1,467.22 | SELL |
Lakshminarayana Bolisetty | 30 Dec 2024 | 31 Dec 2024 | - | 2,000 | ₹1,391.61 | SELL |
TUMMALA VENKAT RAO | 27 Dec 2024 | 31 Dec 2024 | 61,910 | 2,500 | ₹1,380.38 | SELL |
SATYA VANI NANNAPANENI | 28 Feb 2025 | 03 Mar 2025 | 4.20 L | 4.20 L | - | BUY |
SANJAY NANNAPANENI | 28 Feb 2025 | 03 Mar 2025 | 40,000 | 40,000 | - | BUY |
VENKATA SATYA SWATHI KANTAMANI | 20 Mar 2025 | 21 Mar 2025 | 1.59 Cr | 50,000 | - | SELL |
RAJEEV NANNAPANENI | 20 Mar 2025 | 21 Mar 2025 | 10.78 L | 50,000 | - | SELL |
SANJAY NANNAPANENI | 26 Mar 2025 | 27 Mar 2025 | 3.27 L | 2.87 L | - | BUY |
PRAGNYA RAO DONTHINENI | 10 Jun 2025 | 12 Jun 2025 | 403 | 100 | ₹865 | BUY |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1076.87 | +₹129.12 | +13.62% |
| R3 | ₹1027.57 | +₹79.82 | +8.42% |
| R2 | ₹1008.78 | +₹61.03 | +6.44% |
| R1 | ₹978.27 | +₹30.52 | +3.22% |
| PIVOT | ₹959.48 | 11.73 | 1.24% |
| CURRENT | ₹947.75 | - | - |
| S1 | ₹830.37 | -₹117.38 | -12.39% |
| S2 | ₹879.67 | -₹68.08 | -7.18% |
| S3 | ₹910.18 | -₹37.57 | -3.96% |
| S4 | ₹928.97 | -₹18.78 | -1.98% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-73.0% vs avg
8.46L
(13 Mar 2026)Delivery %+14.8% vs avg
42.9%
(13 Mar 2026)Avg Volume (20D)20-day average
3.13M
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
28.1%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Procter & Gamble Health Ltd
158.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Aether Industries Ltd |
 Alivus Life Sciences Ltd |
 Alembic Pharmaceuticals Ltd |
 Astrazeneca Pharma India Ltd |
 Blue Jet Healthcare Ltd |
 Caplin Point Laboratories Ltd |
 Cohance Lifesciences Ltd |
 Concord Biotech Ltd |
 ERIS Lifesciences Ltd |
 Granules India Ltd |
 Jubilant Pharmova Ltd |
 Neuland Laboratories Ltd |
 Procter & Gamble Health Ltd |
 Piramal Pharma Ltd |
 |
 Sanofi India Ltd |
 Sanofi Consumer Healthcare India Ltd |
 Sun Pharmaceutical Industries Ltd |
About
Natco Pharma Ltd
NATCO Pharma Limited is a global pharmaceutical company with a diverse business model encompassing the development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates. Their operations span India, the United States, and other international markets, showcasing a significant reach in the pharmaceutical industry.
A core component of NATCO's business is the production and sale of finished dosage formulations targeting a wide range of therapeutic areas. These formulations are particularly strong in oncology, addressing various cancers including those affecting the blood, liver, kidney, lung, brain, breast, and ovary. Beyond oncology, they also offer products for cardiology and diabetology, specifically targeting conditions like hypertension, stable angina, and congestive heart failure (CHF).
In addition to finished formulations, NATCO Pharma is a significant player in the API market. They manufacture APIs across several therapeutic categories, mirroring the focus of their finished dosage formulations. These categories include oncology, central nervous system treatments, pain management solutions, and cardiovascular care medications. This vertical integration, controlling both API and formulation production, gives them a strategic advantage in the market.
Further diversifying their portfolio, NATCO Pharma provides specialized products in orthopedics, notably bisphosphonates in both oral and injectable forms. They also cater to gastroenterology needs with novel drugs targeting chronic hepatitis B and C. Furthermore, the company offers contract manufacturing services, leveraging their manufacturing expertise to provide services for other pharmaceutical entities.
Beyond human pharmaceuticals, NATCO Pharma extends its reach into the agrochemical sector. They offer a range of solutions for biological pest management, providing tools to control insects, diseases, and weeds across various crops. This expansion into agrochemicals diversifies their revenue streams and demonstrates their adaptability within the broader chemical industry.
COMPANY FACTS - NATCOPHARM
Registered Address
Natco House, Road No 2, Banjara Hills
Hyderabad
TELANGANA
IN
Tel: 914023547532
Website:https://www.natcopharma.co.in/
Investor Relations:https://www.natcopharma.co.in/investors/financial/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 4,016
IPO Date: 23/01/1995
MANAGEMENT - NATCOPHARM
Shri. Venkaiah Nannapaneni
Chairman of the Board, Managing Director, Executive Director
Sri. Rajeev Nannapaneni
Chief Executive Officer, Vice Chairman of the Board, Executive Director
Mr. S. V. V. N. Appa Rao
Chief Financial Officer
Dr. Linga Rao Donthineni
President - Technical Affairs, Executive Director
Sri. Potluri Prasad
Executive Vice President - Corporate Engineering Services, Executive Director
Mr. Rajesh Chebiyam
Executive Vice President - Crop Health Sciences
Dr. Ramesh Dandala
Executive Vice President - Technology Transfer, Intellectual Property Rights and Regulatory Affairs (API)
Dr. M. Pulla Reddy
Executive Vice President - R&D
Mr. Lakshminarayana Are
Senior Vice President - HR & OD
Mr. Imtiyaz Basade
Senior Vice President - RAD
Mr. Srinivas C. H.
Senior Vice President - Demand and Supply Planning
Mr. Bhimrao Jadhav
Senior Vice President - Operations (Formulations)
Investor Questions Answered
Natco Pharma Ltd (NATCOPHARM) Stock FAQs
Get answers to the most common questions about Natco Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Natco Pharma Ltd (NATCOPHARM) is ₹947.75. Today, the stock has declined by ₹8.10 (0.85%), trading in a range of ₹940.7 to ₹990. The stock opened at ₹990 with a trading volume of 4,37,225 shares.
Natco Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹15,842.27 crores, P/E ratio of 10.30, ROE of 11.38%, and ROCE of 32.80%. The dividend yield stands at 0.57%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Natco Pharma Ltd (NATCOPHARM) is ₹1,059, while the 52-week low is ₹726.8. Currently trading at ₹947.75, the stock is 66.5% away from its 52-week low and 10.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Natco Pharma Ltd stock at ₹947.75 depends on multiple factors. The stock is currently trading with a P/E ratio of 10.30 and P/B ratio of N/A. Today's performance shows a loss of 0.85%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Natco Pharma Ltd offers a dividend yield of 0.57%, which means for every ₹100 invested at the current price of ₹947.75, you can expect to receive approximately ₹0.57 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Natco Pharma Ltd's key financial metrics include: P/E Ratio: 10.30, P/B Ratio: N/A, ROE: 11.38%, ROCE: 32.80%, Dividend Yield: 0.57%, EPS: ₹85.91, Book Value: ₹424.71, Debt-to-Equity: 0.04, and Current Ratio: N/A. The company's market cap stands at ₹15,842.27 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Natco Pharma Ltd stock opened at ₹990 and is currently trading at ₹947.75, showing a decline of ₹8.10 (0.85%). The intraday high is ₹990 and low is ₹940.7. The trading volume stands at 4,37,225 shares, indicating moderate market participation today.
Natco Pharma Ltd has a Price-to-Earnings (P/E) ratio of 10.30, which means investors are willing to pay ₹10.30 for every ₹1 of earnings. With an EPS of ₹85.91, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Natco Pharma Ltd has a market capitalization of ₹15,842.27 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹947.75) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Natco Pharma Ltd has a book value of ₹424.71 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹947.75, which is 123.2% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Natco Pharma Ltd has a Return on Equity (ROE) of 11.38% and Return on Capital Employed (ROCE) of 32.80%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
Natco Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Natco Pharma Ltd has a debt-to-equity ratio of 0.04, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Natco Pharma Ltd has an Earnings Per Share (EPS) of ₹85.91, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹947.75 and P/E ratio of 10.30, investors are paying 10.30 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Natco Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Natco Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Natco Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (10.30), ROE (11.38%), debt-to-equity (0.04), and growth rates. 2) Technical Analysis - Check 52-week range (₹726.80 - ₹1059.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹947.75) with book value (₹424.71) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Natco Pharma Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹947.75 is 47288x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Natco Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹726.80 - ₹1059.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.04 indicates leverage. 4) Liquidity Risk - Based on trading volume of 4,37,225 shares. 5) Valuation Risk - P/E of 10.30 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Natco Pharma Ltd operates in the industry with key metrics: P/E ratio of 10.30, ROE of 11.38%, market cap of ₹15,842.27 crores, and dividend yield of 0.57%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.04), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Natco Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹947.75, with a 52-week range of ₹726.80 to ₹1059.00. Based on fundamentals like P/E (10.30), ROE (11.38%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Natco Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹947.75. 2) Fundamental Deterioration - Declining ROE (currently 11.38%), increasing debt (D/E: 0.04), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Natco Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.57%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu